Penetration testing is crucial for medical devices to identify vulnerabilities and ensure regulatory compliance. Unlike generic IT penetration testing, medical device penetration testing requires specialized expertise due to unique device architectures, patient risks, and stringent regulatory demands.
Black-box alone is not enough. FDA expects credentialed testing across every ring.
Recognize that standard IT penetration testing often fails to identify critical vulnerabilities in medical devices due to a lack of understanding of specialized device architecture, patient risks, and regulatory requirements.
Ensure your penetration testing includes specialized protocols like DICOM, HL7/FHIR, MedRadio, and BLE Medical, as these have unique attack surfaces often overlooked by generalist testers.
Go beyond typical IT pentesting by incorporating hardware and firmware analysis techniques such as bus sniffing, JTAG/UART access, firmware extraction, and protocol fuzzing to uncover deeper vulnerabilities.
Do not limit testing to the device itself. Include cloud backends (AWS, Azure, GCP) and mobile companion applications (iOS, Android) to ensure comprehensive security across the whole ecosystem.
Utilize experienced offensive security experts for manual testing to discover logic flaws, business workflow vulnerabilities, and chained exploits that automated scanning tools frequently miss.
Insist on detailed, submission-ready documentation that is specifically tailored to the latest FDA cybersecurity guidance, such as FDA 2026 Premarket Cybersecurity Guidance, to avoid delays and rejections.
Initiate the penetration testing process with a detailed discovery and scoping phase to clearly define the device, its intended use, connectivity, and data flows, leading to a tailored testing plan.
Ring 1: the device itself (firmware, radios, physical interfaces). Ring 2: adjacent ecosystem (companion app, gateway, cloud API). Ring 3: the manufacturer's operations (build pipeline, update infrastructure). A 524B-aligned pentest report should name which rings were tested and why.
A pentest is a point-in-time artifact. Define retest triggers: new interface, new radio, cryptographic change, new third-party component, or 12-month calendar cadence — whichever comes first.
Authoritative guidance and standards underpinning this topic. Always confirm the latest revision with the publisher.
Quick answers to the questions teams most often ask about this topic.
Penetration testing is targeted, hands-on security testing that simulates how a real attacker would try to compromise the device. For FDA submissions it must cover all relevant interfaces (network, wireless, physical, service, cloud) and be performed by a qualified party independent of the development team.
Yes, in practice. The FDA's February 3 2026 premarket cyber guidance expects a penetration test report as part of the security testing evidence. Missing or superficial testing is a common deficiency and can trigger Refuse-to-Accept decisions.
Typical scoped engagements run from roughly $25K for a single-interface, low-complexity device to $150K+ for a complex platform with cloud, mobile, and service interfaces. Scope, methodology, and reporting rigor drive the number more than headline pricing.
A team with demonstrable experience testing embedded devices, familiarity with FDA and MDR expectations, and a documented methodology (typically drawing on OWASP, NIST SP 800-115, and OSSTMM). Testers should be independent of the device's development team.
A significant design change, a new interface, a change in third-party components affecting the attack surface, or a postmarket vulnerability that suggests coverage gaps. Trivial changes typically do not require a full retest but should be documented in the SPDF.
Jump to all guides for the lifecycle phase that fits where you are.